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SUMMARY 
The physical and functional interaction between the transcription factor p53 and its 
negative regulatory partner protein Hdm2 (Mdm2 in mouse) is a key point of 
convergence of multiple signalling pathways that regulate cell proliferation and survival. 
Hdm2 mRNA transcription is induced by p53, forming the basis of an auto-regulatory 
feedback loop. Growth and survival factor-activated Ras-Raf-MEK-ERK signalling can 
also regulate Hdm2 expression independently of p53, contributing to the pro-survival 
effect of these factors. In murine fibroblasts, this occurs through the regulation of mdm2 
mRNA transcription. Here we show that, in human breast cancer epithelial cells, MEK-
dependent regulation of Hdm2 expression also occurs at a post-transcriptional level. 
Pharmacological blockade of MEK activity in T47D cells inhibits Hdm2 protein synthesis 
by 80-90%. This occurs in the absence of changes in the expression of the major hdm2-P1 
mRNA transcript, and only an approximately 40% reduction in hdm2-P2 transcript levels. 
The amounts of both transcripts that are associated with polyribosomes, and are hence 
being actively translated, are reduced by >80% by the MEK inhibitor, U0126. We show 
here that this is due to the inhibition of hdm2 mRNA export from the nucleus when MEK 
activity is inhibited. In MCF-7 breast cancer cells that express wild-type p53, Hdm2 is 
required to suppress p53-dependent transcription when MEK kinase is active.  Regulation 
of the nuclear export of hdm2 mRNA provides, therefore a mechanism whereby mitogen 
stimulated cells avoid p53-dependent cell cycle arrest or apoptosis by maintaining the 
dynamic equilibrium of the Hdm2-p53 feedback loop. 
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INTRODUCTION  
The tumour-suppressor p53 and oncoprotein Hdm2 function within an auto-regulatory 
feedback loop that is a point of convergence of signalling pathways that regulate cellular 
proliferation and survival (1). p53 primarily functions as an activating transcription 
factor, and key p53 target genes include the cyclin-dependent kinase inhibitor WAF1 (2), 
PUMA, which encodes a BH3-domain containing pro-apoptotic molecule (3,4), and hdm2  
(5). Cellular p53 activity is inhibited in proliferating cells and is activated under situations 
such as cellular stress, as part of a growth arrest or apoptosis response. Hdm2 functions 
principally as the primary negative regulator of p53 function (6) and its correct expression 
and function can be essential for the prevention of spontaneous p53-dependent apoptosis 
or cell cycle arrest (7-11). Mechanisms whereby Hdm2 down-regulates p53 function 
include concealing its activation domain from the transcriptional machinery (12), and 
targeting it for ubiquitination, nuclear export and proteosomal degradation (13). 
 
Stress-induced activation of p53 almost invariably involves post-translational 
modifications to both p53 and Hdm2, which can inhibit Hdm2 function (14) or the Hdm2 
- p53 interaction (15-17). Proliferative and pro-survival signalling pathways can also 
impinge upon p53 through either the positive or negative regulation of Hdm2 function. 
AKT kinase, a key enzyme in pro-survival signalling pathways, phosphorylates Hdm2, 
which results in elevated Hdm2 levels in the nucleus (18-20). The growth factor-induced 
Ras-Raf-MEK-ERK signalling pathway can have context dependent effects on 
proliferation and survival (21), and its regulation of the p53 – Hdm2 axis appears to be 
similarly complex. Signalling via this cascade can induce the expression of p14ARF, an 
Hdm2 antagonist, resulting in p53 activation. This can be an important block to cancer 
progression, and p14ARF expression is lost in many tumours (22,23). In contrast, induction 
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of Hdm2 expression by the Ras-Raf-MEK-ERK can play an important role in the 
proliferative and pro-survival response to growth factors (24,25). Indeed, this increased 
expression of Hdm2 may dampen the p53 response to activating signals such as genotoxic 
cancer therapies, particularly in tumour cells in which p14ARF expression is lost (24,25). 
Conversely, transgenic mutations that result in as little as a 20% loss of Mdm2 expression 
in adult mice result in increased sensitivity to radiation (26). 
 
Hdm2 is normally present at very low levels in cells, as the protein directs its own auto-
ubiquitination and is rapidly degraded (27). Elevation of Hdm2 expression occurs at 
varying frequencies in diverse tumour types (28). In a proportion of cancers, this is a 
consequence of hdm2 gene amplification (29), though in many cases, alternative 
mechanisms must underlie the increase (28). Hdm2 expression is regulated by 
transcription from two promoters, P1 and P2 (5). Transcription from P1 is considered to 
be constitutive in most cells (30), whereas P2-promoter activity is highly induced by p53 
(5). The murine mdm2 P2-promoter is also induced by Ras-Raf-MEK-ERK signalling 
(25). Both hdm2 transcripts include the full length coding sequence, but the P1 transcript 
contains a long 5’ untranslated region with two upstream open reading frames, and is 
poorly translated (31). In addition to mRNA transcription, Hdm2 protein levels can also 
be controlled by mRNA translation (31,32) as well as protein turnover (33). Hdm2 
expression is elevated in as many as 50% of breast carcinomas (34-36) and we have 
provided evidence for a role for p53-independent transcription from the P2-promoter in 
this increased expression (37). In this present study we have investigated the role of Ras-
Raf-MEK-ERK signalling in controlling the levels of Hdm2 protein in breast cancer cells, 
and demonstrate a key role for this pathway in regulating the export of hdm2 mRNA to 
the cytoplasm. 
4 





Culture of human breast cancer cell lines- MCF-7 and T47D breast cancer cell lines were 
cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% 
foetal calf serum (Autogen Bioclear) as described previously (37). The following reagents 
were dissolved in dimethyl sulphoxide (DMSO1) at the indicated concentrations before 
adding to the medium where stated; 10 mM U0126 (Promega), 20 mM PD98059 
(Promega), 10 mM MG132 (Sigma). Cycloheximide (Sigma), and 5-fluorouracil (5-FU) 
(David Bull Laboratories) were in aqueous solutions. Nutlin-3 (Alexis Biochemicals) was 
dissolved in ethanol at 5 mM. 
 
Protein analysis- cells were washed with phosphate-buffered saline (PBS), pelleted by 
centrifugation at 1000 g, snap frozen and stored at -80 °C. For immunoblotting, pellets 
were lysed for 15 min at 4 °C in denaturing urea buffer (7 M urea, 0.1 M dithiothreitol 
(DTT), 0.05% Triton X-100, 25 mM NaCl, 20 mM HEPES pH 7.6) then clarified by 
centrifugation at 13000 g for 10 min. Protein concentration was determined by the 
method of Bradford (Biorad). Immunoblotting was performed by standard procedures, as 
described previously (38), and membranes were probed for Hdm2 (monoclonal antibody 
2A9 (39)), p53 (DO-1, Serotec), phospho Thr202/Tyr204 ERK 1 and ERK 2 (E10), total 
ERK 1 and ERK 2 (both from Cell Signalling Technology) or p21WAF-1 (Clone SX118, 
Pharmingen). Equal protein loading was confirmed on all immunoblots using rabbit anti- 
β actin antibody (Sigma). Bands were visualised by chemiluminescence (Supersignal, 
Pierce) using a Fluor-S MAX system (Biorad), and quantified using Quantity One 
software (Biorad).  
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For labelling of newly synthesised proteins, cells were washed twice with labelling 
medium (RPMI medium without methionine, cysteine or L-glutamine (Sigma), 
supplemented with dialysed and heat inactivated foetal calf serum), then incubated with 
labelling medium for 30 min before the addition of fresh labelling medium containing 
0.25 mCi/ml TranS-label (Amersham Biosciences) and incubation at 37 °C for 90 min. 
Cells were then processed as for protein analysis. After the gel was stained using 
Coomassie blue, it was dried and exposed to a phosphor image plate for 5 h. Bands were 
visualised using a Personal Molecular Imager FX (Biorad). 
 
RNA analysis- RNA extraction from cell pellets, and cell fractions, was performed using 
either RNABee (Biogenesis Inc.) or RNAeasy (Qiagen). Ribonuclease protection assay 
(RPA) for hdm2 was performed as previously described (37). For Taqman quantitative 
polymerase chain reaction (qPCR) analysis of hdm2 transcripts, 0.5 - 1 µg of RNA was 
used to generate cDNA, using Superscript II RNAse H- reverse transcriptase (Invitrogen) 
and oligo dT primers, in a 20 µl volume. Oligonucleotide primer pairs and probes were 
designed using Primer Express, version 2.0 (Perkin Elmer Applied Biosystems), and were 
synthesised by MWG Biotech. Each primer sequence lies within a different exon, and the 
fluorogenic probe spans the junction between the two exons. hdm2 coding sequence 
(CDS) primers amplify a region around the exon 9-10 boundary. Primers and probe for 
gapdh, which was used as an endogenous control gene, were purchased as a Pre-
Developed TaqMan® Reagent Assay (Perkin Elmer Applied Biosystems). Analysis was 
performed using the ABI PRISM 7900HT Sequence Detection System instrument and 
software (Perkin Elmer Applied Biosystems). qPCR was performed in 20 µl reaction 
volumes containing 1X qPCR™ Mastermix (Eurogentec), cDNA (from 5 ng of RNA) and 
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one of the following sets of primers and probe: hdm2-CDS-F 
(TCTACAGGGACGCCATCGA) and hdm2-CDS-R 
(CTGATCCAACCAATCACCTGAA) (300 nM each) and hdm2-CDS probe (FAM-
TTCACTTACACCAGCATCAAGATCCGGA–TAMRA) (100 nM); hdm2-P1-F 
(GACTCCAAGCGCGAAAACC) and hdm2-P1-R 
(CCATCAGTAGGTACAGACATGTTGGT) primers (900 nM each) and hdm2-P1 probe 
(FAM-TGCACATTTGCCTGCTCCTCACCAT-TAMRA) (200 nM); hdm2-P2-F 
(CGGACGCACGCCACTT) and hdm2-P2-R 
(CAGTAGGTACAGACATGTTGGTATTGC) primers (900 nM each) and hdm2-P2 
probe (FAM-TTCTCTGCTGATCCAGGCAAATG-TAMRA) (200nM). Ct values were 
converted to relative transcript levels using a standard curve. Semi-quantitative RT-PCR 
was performed as described previously (37); primers used were: gapdh- RT  oligo dT, 
forward GAAGGTGAAGGTCGGAGT, reverse GAAGATGGTGATGGGATTTC; 
scRNA hY4- RT AAAAAGCCAGTCAAATTTAGCA, forward 
GGTCCGATGGTAGTGGGTTA, reverse AAAGCCAGTCAAATTTAGCAGT. 
 
Cellular fractionation prior to RNA extraction or polyribosome analysis was performed 
using hypotonic lysis (40). Cells were washed twice with serum free medium (SFM), then 
scraped in SFM and pelleted by centrifugation at 365 g. Pellets were resuspended in 
hypotonic lysis buffer B (10 mM Tris HCl pH 7.6, 1 mM CH3COOK, 1.5 mM 
CH3COOMg, 2 mM DTT, RNAse inhibitor 1 unit/µl) and cells were lysed on ice using a 
Dounce homogeniser. Lysates were centrifuged at 12,000 g to separate the cytoplasmic 
extract from the nuclear pellet. For some extractions, the lysis buffer was modified where 
indicated (B1, B2, B3).  
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For analysis of polyribosome associated mRNA (40), cycloheximide (10 µg/ml) was 
added to the SFM used to wash the dishes. Cytoplasmic lysates were then layered over a 
cushion of 30% (w/v) sucrose in buffer B and centrifuged at 130,000 g for 2.5 h at 4°C. 
After removing the supernatant, the remaining polyribosome-bound RNA pellet was 
rinsed twice in buffer B before RNA extraction. For fractionation over a sucrose gradient, 
1200 µl cytoplasmic lysate containing 700 µg of protein was layered over a 3.6 ml 
sucrose gradient (15%-55% in buffer B containing 150 µg/ml cycloheximide). This was 
centrifuged at 130,000 g for 2.5 h at 4°C, and 12 x 400 µl fractions were removed for 
analysis. 
 
For in situ hybridisation a 202 base pair region of the hdm2 coding sequence (within 
exons 7-9) was generated using GGTGGGAGTGATCAAAAGGA and 
CCAGGCTTTCATCAAAGGAA primers, and cloned into pGEMTeasy plasmid 
(Promega). Sense and antisense digoxigenin-labelled RNA probes were generated using a 
digoxigenin RNA labelling kit (Roche Diagnostics Ltd.). Cells growing on glass 
coverslips were fixed for 20 min at room temperature with 4% paraformaldehyde in PBS, 
and dehydrated in ethanol before storage at -70 °C, desiccated. Following rehydration, in 
situ hybridisation was performed essentially as described previously (41). Bound probe 
was detected using anti-digoxigenin-rhodamine, Fab fragments (Roche Diagnostics Ltd.), 
and cell nuclei were stained with 4’,6-Diamidine-2’phenylindole dihydrochloride (Roche 
Diagnostics Ltd.). 
 
Plasmids, transfections and reporter gene assays- the hdm2luc03 reporter vector (37) 
contains 165 b.p. of the hdm2-P2 promoter region, including two p53-responsive 
elements, in pGL3Basic (Promega). SuperTIP, which encodes an inhibitor of the p53 – 
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Hdm2 interaction, and the inactive control MutantTIP, have been described previously 
(11). pC53SCX3, which encodes ala143 mutant p53, was a gift of Professor Bert 
Vogelstein. T47D and MCF-7 cells were transfected using Lipofectamine 2000 reagent 
(Invitrogen), and reporter assays were performed using a Dual-GloTM luciferase assay 
(Promega) on cells transfected in 96 well plates, with normalisation to Renilla luciferase 
expressed from pRLSV40 (Promega). The normalised data is presented as relative 
luciferase units (RLU). For transfection of siRNA, reagents were obtained from Qiagen. 
Cells in 60 mm dishes were transfected with 5.5 µg of either control (non-silencing) 
siRNA, or validated siRNA for Hs-mdm2 (hdm2). Transfection was for 24 h, and the 




Pharmacological inhibition of MEK activity suppresses Hdm2 protein synthesis in T47D 
breast cancer cells- compared to a panel of breast cancer cell lines, oestrogen receptor-α 
positive (ERα+ve) lines such as T47D and MCF-7 express relatively high levels of Hdm2 
protein (37). T47D cells express only a transcriptionally inactive mutant p53 protein, and 
therefore this cell line provides a useful model for the study of p53-independent 
mechanisms which regulate the expression of Hdm2. Findings made in this simple model 
can then be extrapolated into the more complex situation present in cell lines such as 
MCF-7, which are more representative of the majority of ERα+ve breast cancers, in which 
changes in Hdm2 expression and p53 activity are dampened by a negative feedback loop 
(42). We determined the effect of pharmacological inhibition of MEK activity on the 
levels of Hdm2 protein in proliferating T47D cells. Consistent with studies in other cell 
types (24,25), 24 h exposure to 25 µM U0126 or 50 µM PD98059, two specific and 
structurally unrelated inhibitors of MEK activity (43), reduced Hdm2 levels by up to 95% 
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(Fig. 1A). Loss of the phosphorylated form of ERK 1 and ERK 2 confirmed that MEK 
was effectively inhibited by 25 µM U0126 in these cells (Fig. 1B). Removal of U0126, 
and the addition of fresh medium, lead to the recovery of Hdm2 to greater than pre-
treatment levels within 2-3 hours (Fig. 1C). This recovery did not occur if U0126 was 
included in the medium (data not shown).  
 
Hdm2 protein is rapidly turned over in most cells. The reduction in Hdm2 protein levels 
in U0126-treated T47D cells is not due to a further increase in the rate of Hdm2 protein 
turnover, as assayed by the rates at which Hdm2 protein levels decrease following the 
inhibition of protein synthesis by cycloheximide (Fig. 2A). 12 h exposure to 25 µM 
U0126 reduced Hdm2 protein levels by 70%, however the half-life of Hdm2 was 
approximately 15 min in both control- and U0126-treated cells. We then investigated 
whether U0126 affects Hdm2 protein synthesis by determining the rate at which Hdm2 
protein accumulates when its primary degradation pathway is blocked by a proteosome 
inhibitor MG132 (this method was used in preference to conventional metabolic labelling 
studies due to the extremely short half life of Hdm2 and our concern that radio-labelling, 
like other inducers of DNA damage (44), would induce post-translational modifications 
of Hdm2 that could affect its activity and hence turnover). The results shown in Fig. 2B 
clearly demonstrate that the rate of Hdm2 synthesis is reduced by approximately 85% 
when MEK activity is inhibited by U0126. Global synthesis of new proteins was not 
inhibited by U0126 in these cells (Fig. 2C). 
 
The effects of inhibiting MEK activity on hdm2 mRNA expression levels- in the murine 
mdm2 gene, the activity of the P2-promoter is inducible by Ras-Raf-MEK-ERK 
signalling (25). We therefore determined the effects of U0126 on the levels of 
endogenous hdm2 P1- and P2-transcript mRNA using two independent techniques; RPA 
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(Fig. 3A) and qPCR on cDNA generated from polyadenylated mRNA (Fig. 3B). Both 
RPA and qPCR clearly show that the levels of the predominant P1 transcript is not 
affected by U0126 treatment and, consistent with this, no U0126-induced changes were 
detected when qPCR analysis was directed towards a region within the hdm2 coding 
sequence. RPA did not detect any large changes in hdm2-P2 mRNA levels following 
U0126 treatment (Fig 3Ai). However, quantitative analysis of multiple independent 
experiments (Fig. 3Aii) identified a small, but significant, difference in –P2 transcript 
levels between DMSO- and U0126 treated cells (100 + 24.2% compared to 70.6 + 15.8%, 
P<0.05). This effect could be more reliably detected by the more sensitive qPCR assay, 
which showed a decrease in the levels of the –P2 transcript by 41.1 +7.0% (n=5) 
following U0126 treatment (Fig. 3B). We had previously been unable to detect this 
relatively small change using semi-quantitative assays (37).  The decrease is unlikely to 
be sufficient to account for the 95% reduction in Hdm2 protein levels that are observed in 
U0126 treated cells as siRNA-mediated knock-down of the hdm2-P2 transcript by 
approximately the same amount as occurs following U0126 treatment, results in only a 
45% reduction in Hdm2 protein levels (Fig. 3C). 
 
MEK inhibitors reduce Hdm2 levels by regulating the export of hdm2 mRNA to the 
cytoplasm- the data described above suggest that inhibition of MEK activity can affect 
Hdm2 protein synthesis at a post-transcriptional level. We therefore set out to establish 
whether this might occur at the level of mRNA trafficking or translation. T47D cells were 
incubated with either U0126, or DMSO control, and then subjected to a gentle hypotonic 
lysis in order to generate cytoplasmic extracts suitable for the subsequent analysis of 
polyribosomes. Initially, qPCR was performed on these extracts to determine levels of 
hdm2 mRNA transcripts (Fig. 4A). This analysis showed that, following U0126 
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treatment, both hdm2 mRNA transcripts are significantly under-represented in these 
cytoplasmic extracts, compared to their levels in total mRNA. Specifically, whilst total 
cellular levels of the hdm2 P1 transcript were unaffected by U0126, levels in the 
cytoplasmic fraction were decreased by 64.2%. Likewise, whilst U0126 decreased overall 
hdm2-P2 expression by approximately 40% as before, the levels of this transcript were 
further under-represented in the cytoplasmic lysates, being reduced by 71.3% compared 
to mock-treated controls. These results suggest that U0126 treatment regulates the export 
of hdm2 mRNA from the nucleus to the cytoplasm. We undertook two further 
experiments to substantiate these findings.  
 
Firstly a more extensive fractionation analysis was performed (Fig 4B). Cell lysis was 
performed with the same hypotonic lysis buffer B as used in the experiment shown in Fig. 
4A and U0126 again resulted in a marked under-representation of both hdm2 transcripts 
in the soluble cytoplasmic extract (S) compared to total cell lysates (T). A corresponding 
increase in hdm2 transcript levels was seen in the nuclear pellets (P) following U0126 
exposure. Semi-quantitative PCR detection of the small cytoplasmic RNA scRNA hY4 
(45) confirmed that the cell lysis technique efficiently separated cytoplasmic RNA from 
the nuclear pellet, whereas gapdh mRNA was present in both fractions. Following U0126 
treatment, hdm2 mRNA clearly becomes associated with the insoluble pellet. The 
hypotonic lysis buffer was therefore modified in order to gain insight into the nature of 
this association. Solublisation of lipid membranes with 0.5 % IGEPAL CA-630 (B2) was 
unable to reverse the U0126-dependent association of hdm2 mRNA with the pellet. 
However addition of 100 mM NaCl to the buffer (B1 and B3) was sufficient to release 
this hdm2 from the nuclear pellet, this being most apparent in the presence of detergent 
(compare buffers B2 with B3).  
12 
Phelps et al  Regulation of Hdm2 expression
  
 
In situ hybridisation experiments were then performed to detect hdm2 mRNA (Fig. 4C). 
In mock-treated control cells, hdm2 mRNA is detectable in the cytoplasm of the cell 
using anti-sense hdm2 RNA probe, but not the control, sense probe. However, in U0126-
treated cells, cytoplasmic hdm2 message can no longer be detected. We were unable to 
detect nuclear hdm2 mRNA in these assays, possibly due to poor access of the probe to 
the target message in the nuclei. 
 
The effects of MEK inhibition on translation of hdm2 mRNA- we next wished to establish 
whether this reduction in the levels of cytoplasmic hdm2 mRNA was reflected in an 
equivalent reduction in rates of hdm2 translation, as assessed by the association of hdm2 
mRNA with high molecular weight polyribosome complexes. Cytoplasmic cell extracts 
were separated through 30% sucrose buffer to isolate polyribosome bound- from free 
cytoplasmic- mRNA (40), and mRNA from total cell extracts and the polyribosome-
associated pellet was then assayed by qPCR (Fig. 5A). Following U0126 treatment, levels 
of hdm2-P1 transcript in the polyribosome-associated fraction was reduced by 75.6%, and 
the –P2 transcript by 83.7%, compared to mock-treated cells. This degree of reduction in 
actively translated hdm2 mRNA transcripts is in good agreement with the 85% reduction 
in the rate of Hdm2 protein synthesis shown in Fig. 2B. The effect of U0126 on the 
amount of polyribosome-associated hdm2 mRNA is largely accounted for by the decrease 
in levels of cytoplasmic message (Fig. 4A), though the effect on polyribosome association 
is slightly greater than that on subcellular localisation, suggesting that a small degree of 
regulation at the level of translation might also be occurring. 
 
13 
Phelps et al  Regulation of Hdm2 expression
  
A more detailed analysis of polyribosome association was then performed using sucrose 
density gradient ultracentrifugation (Fig. 5B). This analysis did not detect any obvious 
shift in the hdm2 message from high to low molecular weight fractions following U0126 
exposure, indicating that U0126 does not inhibit the association of cytoplasmic hdm2 
mRNA with ribosomes in these cells. Rather, there is a reduced level of hdm2 transcripts 
in all fractions in the gradient due primarily to the effect of U0126 on cytoplasmic 
localisation of the message (Fig. 4A). MEK kinase signalling is known to regulate protein 
translation (46), possibly accounting for the apparent shift in the gapdh transcript on the 
profile following U0126 treatment. 
 
Regulation of the p53-Hdm2 auto-regulatory feedback loop by MEK signalling in wild-
type p53-expressing MCF-7 breast cancer cells- inhibiting signalling through the Ras-
Raf-MEK-ERK signalling cascade has previously been shown to have diverse effects in 
the p53 stress response pathway, (25,47-49) and we therefore sought to establish the role 
that control of Hdm2 levels by this pathway has in regulating the p53 response in breast 
cancer cell lines. Firstly, we determined that 24 h exposure to 25 µM U0126 also reduces 
Hdm2 protein levels by >75% in the wild-type p53-expressing cell line, MCF-7 (Fig. 6A). 
U0126 also prevented the induction of Hdm2 protein expression by the p53-activating 
chemotherapeutic agent, 5-FU (Fig. 6B). Interestingly, however, this inhibition did not 
result in increased levels of p53 protein (Fig. 6B), nor was there any clear synergistic 
effect on long term clonogenic survival of co-treatment with 5-FU and U0126 (Fig. 6C), 
that might have indicated that inhibition of Hdm2 expression by U0126 was leading to a 
hyper-activation of the p53 response to genotoxic stress. In fact, we found that U0126 
actually attenuated the activation of p53-dependent transcription by 5-FU in MCF-7 cells 
(Fig. 6D). This inhibition of p53 activity was completely independent of functional Hdm2 
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protein, as demonstrated by two experiments: firstly transcription from a p53-dependent 
reporter vector (Fig. 7A) and an endogenous p53-induced transcript, hdm2-P2 mRNA 
(Fig. 7B) was inhibited by U0126 in cells in which p53 had been activated by a rationally 
designed inhibitor of the Hdm2-p53 interaction, SuperTIP (11); and secondly the 
upregulation of the p53-induced protein, p21WAF-1, by a chemical inhibitor of the Hdm2-
p53 interaction, Nutlin-3 (50) was inhibited by U0126, the Nutlin-3 induced increase in 
Hdm2 protein levels also being partially attenuated. The stabilisation of p53 protein by 
Nutlin-3 was not inhibited by U0126, suggesting that the effects of U1026 on p53 
function occur at the post-translational level. Consequently, signalling through MEK 
kinase impinges on the p53-Hdm2 axis via at least three independent pathways in these 
cells (Fig. 8). 
 
DISCUSSION 
Regulation of Hdm2 expression and function is a key component of several growth factor 
activated pro-survival and proliferative signalling pathways. Increased stability and 
nuclear localisation of Hdm2 protein, following its phosphorylation by AKT kinase, is an 
important component of the anti-apoptotic response to survival factors (18-20). Growth 
factor stimulation also induces Hdm2 / Mdm2 expression (24,51) in a MEK kinase 
dependent manner (25,52). Mosner et al demonstrated that Mdm2 protein expression is 
induced in serum re-stimulated fibroblasts without a detectable increase in total mdm2 
mRNA by Northern blotting (51), suggesting that mdm2 may be regulated at the post-
transcriptional level under these circumstances. However, mdm2 was identified as an 
early response gene induced by platelet-derived growth factor receptor-β signalling in 
murine fibroblasts (53), and AP1 and ETS factor binding sites were identified in the 
murine mdm2 -P2 promoter that regulate its activity in response to Ras signalling (25). 
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Therefore, the findings of Mosner et al (51) could be explained by induction of the 
efficiently-translated mdm2-P2 transcript, which would have been masked on northern 
blots by the more highly expressed constitutive P1-derived message.  
 
Inhibiting Ras signalling or MEK activity has also been shown to down-regulate Hdm2 
protein expression in human cells (25,47). However, whilst the activity of murine hdm2-
P2 reporter vector in human colon carcinoma cells is inhibited by MEK inhibitors, the 
effects of these interventions on the endogenous human hdm2 transcripts, or the human 
P2-promoter, have not been demonstrated previously. In proliferating MCF-7 and T47D 
breast cancer cell lines, a conserved AP1-ETS element in the hdm2-P2 promoter is 
required for the p53-independent expression of the P2-transcript that occurs in these cells 
(37). As we show in this current paper, however, the activity of the hdm2-P2 promoter in 
T47D cells is only partialy dependent on MEK kinase activity. This is in marked contrast 
to the Hdm2 protein synthesis in these cells, which is reduced by up to 95% following 
exposure to MEK inhibitors. Further biochemical and histochemical analysis 
demonstrated that MEK inhibition results in greatly reduced export of both hdm2 -P1 and 
-P2 transcripts from the nucleus to the cytoplasm. 
 
Regulation of the nuclear export of mRNA is a key point of control for the expression of 
a number of cellular proteins, and is one of the most elaborate nuclear transport pathways 
(54). All nuclear mRNAs exist in relatively large complexes with proteins, and it is these 
complexes which interact with components of the nuclear export pathways that are 
responsible for transporting the mRNA from the site of transcription to the cytoplasm. 
Assembly of these mRNA-protein complexes begins during mRNA processing, and the 
complexes include cap binding proteins, splicing factors, and other proteins involved in 
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pre-mRNA processing. During mRNA processing, the mRNA-protein complexes remain 
tightly attached to the nuclear matrix, but at some point following processing, this 
interaction is weakened, and the mRNA can be released from the nucleus by salt 
extraction (55). As far as we are aware, the molecular basis of this observation has not 
been elucidated, and the question of how mRNAs are transported from the site of 
transcription to the nuclear pore complex remains only partly characterised (54). 
Inhibition of MEK activity results in the export of hdm2 mRNA being blocked in this 
nuclear, salt extractable, compartment. At present we can only speculate that this 
represents the regulation, by MEK, of proteins involved in a nuclear export pathway that 
is required for the transport of a subset of mRNAs. Experimental manipulation of specific 
nuclear export processes can be shown to inhibit the expression of early response genes 
such as c-fos (56), and there is an increasing body of evidence suggesting that cellular 
mRNAs can be organised and exported from the nucleus as functionally related groups by 
RNA binding proteins (57). Whether such pathways might be dependent on MEK 
signalling has not been described. It will be of interest to determine what other mRNAs 
are similarly affected by MEK inhibitors, which are known to inhibit the synthesis of a 
number of key regulators of cell cycle progression and apoptosis at a post-transcriptional 
level (58,59). 
 
Another issue raised by our findings is what the effect of this control mechanism might be 
on the ability of Ras-Raf-MEK-ERK signalling to modulate chemo- and radio-sensitivity 
in cancer cells. MEK-dependent expression of proteins such as Hdm2, Bcl-XL, and IAPs, 
at the level of gene transcription and translation, is required for growth and survival 
factors, such as fibroblast growth factor-2, to protect cells from genotoxic agents 
(24,25,58,59). In the case of Hdm2, this is most likely to be through the suppression of 
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the p53 response, and, in cancer cells in which expression of the Hdm2 antagonist p14ARF 
is lost, MEK inhibitors can enhance the cytotoxicity obtained with γ-irradiation (25). We 
therefore examined whether, in the MCF-7 cell line model, there would be a synergistic 
effect between U0126 and the p53-activating anti-metabolite 5-FU, a chemotherapeutic 
agent which can be dependent on p53 activity to kill cancer cells (60), and also shows a 
strong induction of Hdm2 expression at cytotoxic doses. No synergism was observed in 
the colony-forming assays and, instead, we found that U0126 treatment resulted in 
inactivation of p53 function. This is consistent with other previous data showing that 
MEK activity can be required for both the expression of p53 at the transcriptional level 
(61) and the activation of p53 by genotoxic agents (48,49). We also showed that this 
inhibition of p53 activity did not require functional Hdm2 in the cell, as it occurred in the 
presence of the Hdm2 inhibitors SuperTIP and Nutlin-3. This is again consistent with the 
reports that MEK inhibitors inhibit stress-induced phosphorylation of p53 at serine 15, 
which is required for the interaction of p53 with its co-activator, p300 (62), though the 
inhibition of other post-translational modifications, or co-operating transcriptional 
activators, should also be considered. Whilst MEK inhibitors can also inhibit transcription 
of p53 mRNA (61), this is unlikely to be the mechanism of p53 inactivation in our 
experiments, as U0126 does not prevent the accumulation of p53 protein in response to 
Nutlin-3. From a broader perspective, inhibitors of the Ras-Raf-MEK-ERK pathway, and 
particularly MEK inhibitors, have good potential as anti-cancer agents (63). However, 
their ability to potentiate the effects of genotoxic chemotherapeutic agents appears to be 
highly dependent on the target cell type and agent being studied (64,65). 
 
Together, our data suggest a model by which the p53-Hdm2 feedback loop is regulated in 
response to mitogenic or anti-apoptotic signalling through the Ras-Ras-MEK-ERK 
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signalling pathway, at least in the breast cancer cell lines we have studied here. In the 
absence of MEK activity, cells reduce their proliferation rate and enter a G1 arrest phase 
(data not shown); this is associated with a loss of p53 activity, possibly due to reduced 
serine 15 phoshorylation and p300 binding. Hdm2 expression is therefore not necessary 
to inhibit p53 function, and Hdm2 protein synthesis is decreased, due to both reduced 
transcription from the P2 promoter, and through reduced nuclear export of hdm2 mRNA. 
Following activation of Ras-Raf-MEK-ERK signalling by growth factors, the block to 
hdm2 nuclear export is released, allowing expression of the Hdm2 protein, which is now 
required as p53 activity increases. This helps establish a dynamic equilibrium between the 
p53 and Hdm2 proteins in proliferating cells that is exquisitely sensitive to regulation by 
other signalling pathways, such as those induced by cellular stress. 
 
Hdm2 shows promise as a target for anti-cancer therapies (66), and small molecule 
inhibitors of the p53-Hdm2 interaction that have good efficacy against wild-type p53-
expressing tumour cells in pre-clinical modes have recently been described (50). 
Presumably, such compounds will only be effective in cells in which the target molecule 
is expressed, and in which its activity is required for cellular survival or proliferation. In 
the specific case of breast cancer, which may well be a suitable target for such 
interventions, we have previously demonstrated that elevated levels of Hdm2 protein in 
proliferating cultures of breast cancer cell lines with ERα+ve, compared to ERα-ve, 
phenotypes, correlates with transcription from the P2-promoter of the hdm2 gene in the 
ERα+ve cells (37). In breast tumour samples, Hdm2 protein is over-expressed compared to 
normal cells in as many as 50% of cases (34-36), however in most cases in which Hdm2 
expression is observed in breast cancer, it is limited to small patches of cells in the 
tumour (34). Additionally, one study determined that, of the tumours in which hdm2 
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mRNA was up-regulated, only 69% showed Hdm2 protein over-expression (35). Our data 
support a model in which differences in Hdm2 expression between cancers with different 
phenotypes and differentiation status is defined at the transcriptional level. However 
either specific mutations, or the local tumour environment, that affect signalling through 
the Ras-Raf-MEK-ERK cascade, superimpose upon the transcriptional phenotype by 
regulating Hdm2 protein expression at the level of nuclear export of its mRNA. Whilst 
our study has focussed specifically on breast cancer cell lines, it is likely that this pattern 
of Hdm2 regulation will be prevalent amongst many cancer types in which Hdm2 protein 
is highly expressed. 
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FIG. 1. MEK kinase activity is required for Hdm2 protein expression in T47D breast 
cancer cells. (A) T47D cells were cultured in the presence of DMSO control (D, 7 h) or 
MEK inhibitors PD98059 (50 µM) or U0126 (25 µM) for the indicated time before Hdm2 
proteins levels were determined by western blotting using 2A9 antibody (a second Hdm2 
antibody, 2A10, gave similar results (data not shown)). For quantification, Hdm2 levels 
were normalised to the β actin loading control (open bars – DMSO, grey bars – PD98059, 
black bars – U0126). (B) T47D cells were incubated with DMSO or 25 µM U0126 for 18 
h before expression of the indicated proteins was determined. (C) Cells were incubated as 
in Fig. 1B, then refed with drug-free medium and incubated for a further 0-5 h before 
lysis and western blotting analysis. 
 
FIG. 2. MEK inhibitors block Hdm2 protein synthesis. (A) T47D cells were cultured 
with DMSO carrier or 25 µM U0126 for 12 h before 100 µg/ml cycloheximide (CHX) 
was added to the medium to block new protein synthesis. Normalised Hdm2 protein 
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levels are shown in the bar graph. The line graph shows the percentage of Hdm2 levels in 
either DMSO- or U0126-treated cells relative to levels prior to the addition of 
cycloheximide. Black graphics – DMSO treated, grey graphics – U0126 treated. 
Representative of three independent experiments. (B) T47D cells were cultured with 
DMSO or 25 µM U0126 for 18 h before 50 µM MG132 was added to the medium to 
block proteosome-mediated degradation of Hdm2. Cells were cultured for a further 0-90 
min, then lysed and analysed by quantitative western blotting. Normalised Hdm2 protein 
levels are shown in the bar graph as in Fig. 2A. Lines show linear regression of these data 
over the first 60 min after MG132 addition. Rate of Hdm2 protein accumulation over this 
period in U0126-treated cells was 13.6% of controls. Representative of two independent 
experiments. (C) T47D cells were exposed to 25 µM U0126 (U) or DMSO (D) for 24 h 
before being labelled with 35S-methionine/cysteine for 90 min in the presence of the same 
treatment. Equal protein amounts were run on SDS-PAGE gels that were then analysed 
by Coomassie blue staining for total protein and autoradiography for newly synthesised 
protein. Similar results were obtained with a 30 min labelling period (not shown). Cells 
treated identically in parallel were analysed by western blotting for Hdm2.  
 
FIG. 3. Effects of inhibiting MEK activity on hdm2 mRNA levels. (A) Total cellular 
RNA was analysed by RPA using an hdm2 exon 2 – exon 3 probe, with a gapdh probe as 
a loading control. (Ai) shows a representative experiment. Lanes are: 1, non-digested 
probe; 2, digested probe; m, size markers; 5 and 6, mRNA from T47D cells which had 
been treated for 24 h with DMSO or 25 µM U0126 respectively. (Aii) Shows quantitation 
of RPA analysis of 4 independently treated sets of cells. Open bars – DMSO controls, 
black bars – U0126 treated. Data is normalised to gapdh mRNA levels, and is expressed 
as mean + SEM (B) Total cellular RNA from T47D cells was analysed by qPCR. hdm2 
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mRNA levels were normalised to gapdh housekeeping gene expression, and normalised 
hdm2 mRNA levels in U0126-treated (25 µM, 24 h) cells are expressed as a percentage of 
levels in DMSO-treated cells. Data are mean + S.E.M. for five independently treated sets 
of samples. Western blots confirmed that Hdm2 protein levels decreased in cells treated 
in parallel to the experiments shown in Fig. 3A and B (not shown). (C) T47D cells were 
transfected with control, non-silencing siRNA (lanes- C), or hdm2 specific siRNA (lanes 
–h). 48 h after transfection, cells were analysed for levels of Hdm2 protein (open bars, 
and western blot) and hdm2 mRNA (solid bars). The hdm- P2 transcript levels are shown, 
however the hdm2-specific siRNA targets both -P1 and -P2 transcripts.  
 
FIG. 4. Inhibition of MEK reduces levels of hdm2 mRNA transcripts in the 
cytoplasm. T47D cells were cultured for 24 h with either DMSO carrier, or 25 µM 
U0126. (A) RNA was extracted from either whole cell pellets, or cytoplasmic lysates 
prepared using hypotonic buffer B, and levels of hdm2-P1 and –P2 transcripts determined 
by qPCR. Data is normalised to gapdh. Open bars- DMSO treated, solid bars- U0126 
treated. Error bars are S.D. of duplicate qPCR assays. (B) Cells were extracted using 
either buffer B, or buffer B with the following modifications - B1 (B + 100 mM NaCl), 
B2 (B + 0.5% IGEPAL CA-630), B3 (B + 100 mM NaCl + 0.5% IGEPAL CA-630). 
Hdm2 transcript levels in the soluble cytoplasmic extract (S), or the insoluble nuclear 
pellet (P), as well as in total cell extracts (T), were determined by qPCR. Data are 
presented as in Fig. 4A. Cellular fractionation was validated using semi-quantitative PCR 
for scRNA hY4, and gapdh. Two PCRs for each extraction method are shown, with a two-
fold difference in the amount of input cDNA to confirm the PCRs have not plateaued. (C) 
hdm2 mRNA was detected by in situ hybridisation using antisense hdm2 probe. Control, 
sense, probe is also shown. Dotted white lines outline the position of the cell nuclei. 
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FIG. 5 Effect of MEK inhibitors on the levels of polyribosome-associated hdm2 
mRNA. T47D cells were incubated with either 25 µM U0126, or DMSO carrier for 24 h. 
(A) Polyribosome-associated RNA was then isolated by lysis in buffer B, followed by 
centrifugation of the cytoplasmic lysate through 30% sucrose buffer. qPCR analysis of 
hdm2 transcript levels was performed on total-cell (solid bars) and polyribosome-
associated (open bars) RNA. Data are presented as a percentage of levels in DMSO-
treated cells, and are mean + S.D. for two independent experiments. Hdm2 protein levels 
were analysed in parallel and were reduced by approximately 90% in U0126-treated cells 
(data not shown). (B) Cytoplasmic extracts (from the experiment shown in Fig. 4A) 
containing equal amounts of protein were separated on a 15-55% sucrose gradient. 12 
consecutive fractions were taken from the gradient. 12.5% of the RNA from each fraction 
was used to synthesise cDNA, which was then analysed by qPCR. Upper panel- relative 
protein concentration (Bradford assay); second panel- agarose gel electrophoresis to 
detect the major ribosomal RNAs; lower panels- levels of the indicated mRNA transcripts 
in each fraction. y axis is the same for both DMSO and U0126-treated cells.  
 
FIG. 6. Effect of inhibiting MEK activity on the p53-Hdm2 feedback loop in wild-
type p53-expressing breast cancer cells. (A) Hdm2 expression in MCF-7 cells 
following incubation with 25 µM U0126 or DMSO for the indicated times. (B and C) 1.5 
x 106 MCF-7 cells were plated per 90 mm dish and 48 h later re-fed with medium 
containing 25 µM U0126, or DMSO. After a further 24 h, 200 µM 5-FU was added where 
indicated, and all dishes incubated for a further- (B) 4 h before cell pellets were made for 
western blotting analysis or- (C) 6 h before plates were trypsinised, 2 x 104 cells plated in 
a new dish, and cultured for a further 14 days before cells were fixed and stained with 
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Giemsa. (D) MCF-7 cells were transfected with a minimal p53-responsive reporter 
construct (hdm2luc03) and refed with medium containing 25 µM U0126 (solid bars) or 
DMSO carrier (open bars) plus the indicated concentration of 5-FU. Reporter gene 
activity was assayed 40 h later. Results are mean + S.D. of duplicate dishes and are 
representative of two independent experiments.  
 
FIG. 7. Inhibition of MEK kinase in MCF-7 cells inhibits p53-dependent 
transcription independently of Hdm2 protein function. (A) MCF-7 cells were 
transfected with hdm2luc03 or pGL3basic reporter plasmids plus plasmids encoding 
either SuperTIP (S-TIP, an inhibitor of the Hdm2:p53 interaction), the inactive control 
vector, MutantTIP (M-TIP), or dominant negative (ala143) mutant p53. Following 
transfection, cells were incubated for 48 h in the presence of 25 µM U0126 (solid bars) or 
DMSO control (open bars) before reporter activity was assayed. Data are mean + S.D. for 
duplicate dishes. Representative of >3 separate experiments. (B) MCF-7 cells were 
transfected with either SuperTIP or MutantTIP plasmids and then cultured for 24 h in the 
presence of 25 µM U0126 (solid bars) or DMSO (open bars) for 24 h. qPCR was 
performed for the p53-responsive hdm2-P2 transcript, levels of which are normalised to 
gapdh control. Data are mean of duplicate assays. (C) MCF-7 cells were cultured in the 
presence of vehicle control (DMSO) or U0126 (25µM) for 24 hours, before Nutlin-3 
(5µM) or vehicle control (ethanol) was added to the media and the cells harvested after 
the indicated time. Hdm2, p53 and p21 protein levels were determined by Western 
blotting. 
 
FIG. 8 MEK signalling maintains the p53-Hdm2 feedback loop in a state of dynamic 
equilibrium in cancer cells. The three distinct points of regulation described in this 
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manuscript are: [1] MEK activity promotes the Hdm2-independent activation of p53 as a 
sequence-specific transcriptional activator of genes that promote cell cycle arrest and 
apoptosis. This activation is counteracted by a MEK-dependent increase in both the 
transcription [2] and nuclear export [3] of hdm2 mRNA, which together prevent 
spontaneous p53-dependent growth arrest or apoptosis occurring in cancer cells following 
activation of the growth factor–Ras-Raf-MEK signalling cascade. Note this diagram does 
not include the MEK-dependent activation of the Hdm2 antagonist, p14ARF, which is not 
expressed in MCF-7 breast cancer cells (67). 
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